Trastuzumab deruxtecan

About

Therapy type: Targeted therapy

Therapy strategy: HER2 inhibition

Mappings

NCI Thesaurus: Trastuzumab Deruxtecan (ncit:C128799)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) FDA (1) HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) FDA (1) ERBB2 oncogenic variants Non-Small Cell Lung Cancer Trastuzumab deruxtecan
EMA (1) FDA (1) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
FDA (1) HER2-positive Any solid tumor Trastuzumab deruxtecan
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ERBB2 amplification Non-Small Cell Lung Cancer Trastuzumab deruxtecan
EMA (1) ERBB2 amplification Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
EMA (1) ER positive, HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (1) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab deruxtecan